Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma

Background

Immune checkpoint inhibitors (ICIs) have transformed outcomes for advanced/metastatic melanoma and non-small-cell lung cancer (NSCLC), allowing for a growing population of ICI durable responders (ICI-DR). Despite improved survival, ICI-DR patients may face persistent health-related quality of life (HRQoL) challenges and these are poorly documented. The QUALICI study aimed to describe HRQoL and factors associated with better HRQoL outcomes, patients' experience, and expectations toward HRQoL in ICI-DR patients with advanced/metastatic NSCLC or melanoma. Patients and methods: QUALICI was a multicenter, cross-sectional study conducted in 16 French hospitals. All ICI-DR adults (≥2 years since ICI initiation, no subsequent cancer therapy) were screened and randomly selected to participate and complete questionnaires assessing HRQoL (EuroQol 5 Dimensions 5 Levels [EQ-5D-5L]), social difficulties [Social Difficulties Inventory (SDI)], fatigue (Chalder Fatigue Scale), and care experience.